NEUROCRINE BIOSCIENCES INC

NASDAQ: NBIX (Neurocrine Biosciences, Inc.)

最近更新时间: 25 Jun, 10:28AM

127.23

-0.95 (-0.74%)

前收盘价格 128.18
收盘价格 127.73
成交量 120,754
平均成交量 (3个月) 1,435,850
市值 12,591,419,392
市盈率 (P/E TTM) 43.13
预期市盈率 (P/E Forward) 24.57
价格/销量 (P/S) 5.43
股市价格/股市净资产 (P/B) 4.94
52周波幅
84.23 (-33%) — 157.98 (24%)
利润日期 30 Jul 2025 - 4 Aug 2025
营业毛利率 12.68%
营业利益率 (TTM) 4.14%
稀释每股收益 (EPS TTM) 2.95
季度收入增长率 (YOY) 11.10%
季度盈利增长率 (YOY) -81.80%
总债务/股东权益 (D/E MRQ) 19.45%
流动比率 (MRQ) 3.13
营业现金流 (OCF TTM) 529.90 M
杠杆自由现金流 (LFCF TTM) 235.48 M
资产报酬率 (ROA TTM) 8.75%
股东权益报酬率 (ROE TTM) 12.43%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看跌 混合的
Drug Manufacturers - Specialty & Generic (全球的) 混合的 混合的
股票 Neurocrine Biosciences, Inc. 看跌 看跌

AIStockmoo 评分

-1.1
分析师共识 -0.5
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 -5.0
技术振荡指标 2.0
平均 -1.13

相关股票

股票 市值 DY P/E(TTM) P/B
NBIX 13 B - 43.13 4.94
UTHR 14 B - 12.62 1.90
VTRS 11 B 5.15% - 0.690
HCM 3 B - 77.40 3.47
LNTH 6 B - 23.06 4.80
ALVO 3 B - - -

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Mid Core
内部持股比例 1.09%
机构持股比例 98.86%
52周波幅
84.23 (-33%) — 157.98 (24%)
目标价格波幅
115.00 (-9%) — 185.00 (45%)
185.00 (Evercore ISI Group, 45.41%) 购买
154.00 (21.04%)
115.00 (BMO Capital, -9.61%) 保留
平均值 153.67 (20.78%)
总计 8 购买, 1 保留
平均价格@调整类型 116.18
公司 日期 目标价格 调整类型 价格@调整类型
RBC Capital 02 Jun 2025 145.00 (13.97%) 购买 124.56
06 May 2025 145.00 (13.97%) 购买 118.92
BMO Capital 06 May 2025 115.00 (-9.61%) 保留 118.92
Canaccord Genuity 06 May 2025 160.00 (25.76%) 购买 118.92
28 Apr 2025 158.00 (24.18%) 购买 106.46
Guggenheim 06 May 2025 165.00 (29.69%) 购买 118.92
Needham 06 May 2025 139.00 (9.25%) 购买 118.92
15 Apr 2025 138.00 (8.46%) 购买 96.16
Piper Sandler 06 May 2025 154.00 (21.04%) 购买 118.92
UBS 06 May 2025 152.00 (19.47%) 购买 118.92
04 Apr 2025 137.00 (7.68%) 购买 95.65
Evercore ISI Group 24 Apr 2025 185.00 (45.41%) 购买 105.76
HC Wainwright & Co. 22 Apr 2025 168.00 (32.04%) 购买 101.74
显示更多

该时间范围内无数据。

日期 类型 细节
30 Jun 2025 公告 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
27 Jun 2025 公告 Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
20 Jun 2025 公告 Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
09 Jun 2025 公告 Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
02 Jun 2025 公告 Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
30 May 2025 公告 Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
28 May 2025 公告 Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
16 May 2025 公告 Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
16 May 2025 公告 Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
15 May 2025 公告 Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
14 May 2025 公告 Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
08 May 2025 公告 Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
06 May 2025 公告 Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
06 May 2025 公告 Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
05 May 2025 公告 Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
05 May 2025 公告 Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
30 Apr 2025 公告 Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
24 Apr 2025 公告 Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
14 Apr 2025 公告 Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
04 Apr 2025 公告 Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票